Follow Us
© 2026 Arizent. All rights reserved.
A rivalry is heating up between AstraZeneca and Johnson & Johnson in lung cancer.
The U.S. company’s new drug combination beat Astra’s best-seller Tagrisso in a study presented on Monday at Europe’s biggest cancer conference. But the U.K. drugmaker’s earlier rival findings show Tagrisso can be made effective when paired with chemotherapy.
For reprint and licensing requests for this article, click here.
Chronic conditions like diabetes, heart disease, cancer, and autoimmune disorders affect more than 60% of Americans —
Advancing Chronic Care: Strategic Support for Health and Cost Management
In the age of GLP-1s, balancing costs with providing access to weight care has become a challenge for benefits leaders.
When employees face a serious medical condition, the impact on their health and financial well-being can be devastating.
By offering a quick and simple testing option, benefit leaders can set employees on a path to better health.
